Systematic review of statistical methods used in molecular marker studies in cancer

Cancer

Volumn 112, Issue 8, 2008, Pages 1862-1868

  Vickers, Andrew J ^a   Jang, Kwang ^b   Sargent, Daniel ^c   Lilja, Hans ^a   Kattan, Michael W ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

^c MAYO CLINIC   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Biomedical research; Neoplasms; Research design; Tumor markers

Indexed keywords

MOLECULAR MARKER;

ARTICLE; BODY FLUID; CHEMICAL ANALYSIS; HISTOCHEMISTRY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; OUTCOMES RESEARCH; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

FORECASTING; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 42149185603     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23365     Document Type: Article

References (23)

1. Lilja H, Ulmert D, Bjork T, et al. Long-term prediction of prostate cancer in a large, representative Swedish cohort: prostate kallikreins measured at age 44-50 predict prostate cancer up to 25 years before diagnosis. J Clin Oncol. 2007;25:431-436.
2. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005;353:1224-1235.
3. Sanchini MA, Gunelli R, Nanni O, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA. 2005;294:2052-2056.
4. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-791.
5. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
6. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196-1206.
7. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-991.
8. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845-856.
9. Barlow WE, Chi C, Carney PA, et al. Accuracy of screening mammography interpretation by characteristics of radiologists. J Natl Cancer Inst. 2004;96:1840-1850.
10. Burke HB. Outcome prediction and the future of the TNM staging system. J Natl Cancer Inst. 2004;96:1408-1409.
11. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-1184.
12. Pajak TF, Clark GM, Sargent DJ, McShane LM, Hammond ME. Statistical issues in tumor marker studies. Arch Pathol Lab Med. 2000;124:1011-1015.
13. Kattan MW. Evaluating a new marker's predictive contribution. Clin Cancer Res. 2004;10:822-824.
14. Harrell FEJ. Regression Modelling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
15. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23:2020-2027.
16. Biganzoli E, Boracchi P, Marubini E. Biostatistics and tumor marker studies in breast cancer: design, analysis and interpretation issues. Int J Biol Markers. 2003;18:40-48.
17. Sargent D, Allegra C. Issues in clinical trial design for tumor marker studies. Semin Oncol. 2002;29:222-230.
18. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst. 2005;97:1043-1055.
19. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst. 2007;99:236-243.
20. Conley BA, Taube SE. Prognostic and predictive markers in cancer. Dis Markers. 2004;20:35-43.
21. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295:1658-1667.
22. Steyerberg EW, Vickers AJ. Decision curve analysis: a discussion. Med Decis Making. 2008;28:146-149.
23. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565-574.